Дело T-***/**: *****************, Определение от **.**.2018 г.

Текст

... ication for interim measures — New application — No new facts — Inadmissibility)

In Case T‑347/18 R II,

Laboratoire Pareva, established in St. Martin de Crau (France), represented by K. Van Maldegem and S. Engelbert, lawyers,

applicant,

v

European Commission, represented by R. Lindenthal and K. Mifsud-Bonnici, acting as Agents,

defendant,

APPLICATION pursuant to Articles 278 TFEU and 279 TFEU seeking, first, suspension of operation of Commission Implementing Regulation (EU) 2018/613 of 20 April 2018 approving PHMB (1415; 4.7) as an existing active substance for use in biocidal products of product-types 2 and 4 (OJ 2018 L 102, p. 1), and, secondly, the adoption of any other appropriate interim measure,

THE PRESIDENT OF THE GENERAL COURT

makes the following

Order

Background to the dispute, procedure and forms of order sought by the parties

1. The applicant, Laboratoire Pareva, is a manufacturer of the substance polyhexamethylene biguanide hydrochloride (‘PHMB (1415; 4.7)’) in the European Union.

2. By order of 24 August 2018, Laboratoire Pareva and Biotech3D v Commission (T‑337/18 R and T‑347/18 R, not published, ‘the first order for interim measures’, EU:T:2018:587), the President of the General Court dismissed the application for interim measures lodged by the applicant (‘the first application for interim relief’), seeking, inter alia, suspension of operation of Commission Implementing Regulation (EU) 2018/613 of 20 April 2018 approving PHMB (1415; 4.7) as an existing active substance for use in biocidal products of product-types 2 and 4 (OJ 2018 L 102, p. 1; ‘the contested regulation’).

3. The dismissal ...